Ongoing treatment(s)-Hormonal therapy Posts on Medivizor

Evaluating the long-term effectiveness and safety of enzalutamide plus androgen deprivation therapy in patients with metastatic hormone-sensitive prostate cancer.

Posted by Medivizor on Jul 7, 2024 in Prostate cancer | 0 comments

In a nutshell This study reported the long-term effectiveness and safety of enzalutamide (Xtandi) in combination with androgen deprivation therapy (ADT) for the treatment of patients with metastatic hormone-sensitive prostate cancer (mHSPC). The data showed that enzalutamide in combination with ADT improved the overall survival over the long term with...

Evaluating the long-term effectiveness and safety of adding abiraterone acetate and prednisolone with or without enzalutamide in patients with metastatic prostate cancer starting androgen-deprivation therapy.

Posted by Medivizor on May 26, 2024 in Prostate cancer | 0 comments

In a nutshell The study evaluated the long-term effectiveness and safety outcomes of adding abiraterone acetate (AA; Zytiga) and prednisolone (P; Deltasone) with or without enzalutamide (Xtandi) in patients with metastatic prostate cancer (PC) starting androgen-deprivation therapy (ADT). The data showed that enzalutamide and AA+P should not be combined...

Evaluating the long-term effectiveness and safety of abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer

Posted by Medivizor on Jul 2, 2023 in Breast cancer | 0 comments

In a nutshell The study evaluated the follow-up results of abemaciclib (Verzenio) plus endocrine (hormonal) therapy in patients with hormone receptor-positive (HR+), HER2-negative (HER2-), node-positive, and high-risk early breast cancer (BC). The data found that with a 4-year follow-up, adjuvant abemaciclib continued to show improvement in reducing the...

Evaluating the bone mineral density screening rates and their association with fracture rates among older men with prostate cancer receiving androgen deprivation therapy.

$Evaluating the bone mineral density screening rates and their association with fracture rates among older men with prostate cancer receiving androgen deprivation therapy.$

Posted by Medivizor on Sep 17, 2022 in Prostate cancer | 0 comments

In a nutshell This study evaluated the bone mineral density (BMD) screening rates and their association with fracture rates among older men with prostate cancer (PC) receiving androgen deprivation therapy (ADT). The data showed that BMD screening is associated with a lower major fracture risk in these patients. Some background Prostate...

Evaluating the effectiveness and safety of adding abiraterone acetate and prednisolone with or without enzalutamide to androgen-deprivation therapy in patients with high-risk non-metastatic prostate cancer.

Posted by Medivizor on May 31, 2022 in Prostate cancer | 0 comments

In a nutshell The study evaluated the effectiveness and safety outcomes of adding abiraterone acetate (AA; Zytiga) and prednisolone (P; Deltasone) with or without enzalutamide (Xtandi) to androgen-deprivation therapy (ADT) in patients with high-risk non-metastatic prostate cancer (PC). The data showed that AAP added to ADT significantly improved survival...

Evaluating the effectiveness and safety of 225Ac-PSMA-617 after treatment with androgen deprivation therapy in patients with metastatic castration-resistant prostate cancer.

Posted by Medivizor on May 31, 2022 in Prostate cancer | 0 comments

In a nutshell This study evaluated the effectiveness and safety of actinium-225 [225Ac]-PSMA-617 (225AcPSMA) after treatment with androgen deprivation therapy (ADT) in patients with metastatic castration-resistant prostate cancer (mCRPC). The data showed that 225AcPSMA treatment showed a higher response with manageable effects in these patients. Some...

Evaluating the effectiveness of antiresorptive drugs on bone mineral density in postmenopausal women with early-stage breast cancer receiving treatment with aromatase inhibitors.

Posted by Medivizor on May 31, 2022 in Breast cancer | 0 comments

In a nutshell This study evaluated the effectiveness of antiresorptive drugs on bone mineral density (BMD) in postmenopausal women with early-stage breast cancer (BC) receiving treatment with aromatase inhibitors (AIs). The data showed that denosumab (Prolia) and zoledronic acid (Aclasta) were the most effective antiresorptive treatment options to...

Comparing the effectiveness and safety of abiraterone acetate and enzalutamide for the treatment of metastatic castration-resistant prostate cancer.

Posted by Medivizor on May 8, 2022 in Prostate cancer | 0 comments

In a nutshell This study compared the effectiveness and safety of abiraterone acetate (Zytiga; AA) and enzalutamide (Xtandi; ENZ) in patients with metastatic castration-resistant prostate cancer (mCRPC). The data showed that both medication improve outcomes compared to placebo and ENZ is more effective in improving survival without cancer...

Does sipuleucel-T improve the survival of men with advanced prostate cancer treated with androgen receptor-targeting drugs?

Posted by Medivizor on Apr 10, 2022 in Prostate cancer | 0 comments

In a nutshell This study evaluated the effectiveness of adding sipuleucel-T (Provenge) androgen receptor-targeting agents (ARTAs) such as abiraterone acetate (AA; Zytiga) and enzalutamide (Xtandi) in men with metastatic castration-resistant prostate cancer (mCRPC). The data showed that those receiving both sipuleucel-T and ARTAs were more...

Evaluating the effects of physical therapies on improvement in psychosomatic symptoms and quality of life in patients with breast cancer treated with aromatase inhibitors.

Posted by Medivizor on Feb 13, 2022 in Breast cancer | 0 comments

In a nutshell This study evaluated the effects of physical therapies on improvement in psychosomatic symptoms and quality of life (QoL) in patients with breast cancer (BC) treated with aromatase inhibitors (AIs). The data showed that acupuncture can significantly reduce pain intensity and exercise training might improve QoL in these...

Comparing the effectiveness and safety of apalutamide with darolutamide for non-metastatic castration-resistant prostate cancer.

Posted by Medivizor on Dec 19, 2021 in Prostate cancer | 0 comments

In a nutshell The study compared the effectiveness and safety outcomes of androgen-deprivation therapy (ADT) with either apalutamide (Erleada) or darolutamide (Nubeqa) for the treatment of non-metastatic castration-resistant prostate cancer (CRPC). The data showed that apalutamide plus ADT was safe and more effective in improving...

Evaluating the effectiveness and safety of ipatasertib plus abiraterone and prednisolone for the treatment of patients with metastatic castration-resistant prostate cancer.

Posted by Medivizor on Aug 29, 2021 in Prostate cancer | 0 comments

In a nutshell This study evaluated the effectiveness and safety outcomes of ipatasertib (GDC-0068) in combination with abiraterone acetate (Zytiga) plus prednisone (Deltasone) (AAP) for the treatment of patients with previously untreated metastatic castration-resistant prostate cancer (mCRPC). The data showed that ipatasertib plus...

Ongoing treatment(s)-Hormonal therapy Posts on Medivizor

Evaluating the long-term effectiveness and safety of enzalutamide plus androgen deprivation therapy in patients with metastatic hormone-sensitive prostate cancer.

Evaluating the long-term effectiveness and safety of adding abiraterone acetate and prednisolone with or without enzalutamide in patients with metastatic prostate cancer starting androgen-deprivation therapy.

Evaluating the long-term effectiveness and safety of abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer

Evaluating the bone mineral density screening rates and their association with fracture rates among older men with prostate cancer receiving androgen deprivation therapy.

Evaluating the effectiveness and safety of adding abiraterone acetate and prednisolone with or without enzalutamide to androgen-deprivation therapy in patients with high-risk non-metastatic prostate cancer.

Evaluating the effectiveness and safety of 225Ac-PSMA-617 after treatment with androgen deprivation therapy in patients with metastatic castration-resistant prostate cancer.

Evaluating the effectiveness of antiresorptive drugs on bone mineral density in postmenopausal women with early-stage breast cancer receiving treatment with aromatase inhibitors.

Comparing the effectiveness and safety of abiraterone acetate and enzalutamide for the treatment of metastatic castration-resistant prostate cancer.

Does sipuleucel-T improve the survival of men with advanced prostate cancer treated with androgen receptor-targeting drugs?

Evaluating the effects of physical therapies on improvement in psychosomatic symptoms and quality of life in patients with breast cancer treated with aromatase inhibitors.

Comparing the effectiveness and safety of apalutamide with darolutamide for non-metastatic castration-resistant prostate cancer.

Evaluating the effectiveness and safety of ipatasertib plus abiraterone and prednisolone for the treatment of patients with metastatic castration-resistant prostate cancer.

Categories

Recent Posts

Archives

Ongoing treatment(s)-Hormonal therapy Posts on Medivizor

Categories

Recent Posts

Archives

Thanks for your interest in Medivizor

Invalid email